Fig. 3
hCBPL improves the therapeutic efficacy of adCD-MSCs. Mice received 1.5 % of DSS with their drinking water for 9 days. At days +7, +9, and +11 from DSS induction, mice were treated by enema with adCD-MSCs (1 × 106 cells/mice/time) with or without human umbilical cord blood-derived platelet lysate (hCBPL) or phosphate saline buffer (PBS) alone. Clinical evolution of colitis is monitored by body weight change and DAI evaluation. a Body weight changes during the course of the experiment are expressed as the percentage of the initial body weight at day +0. (Top) Schematic of the experiment. CTR, healthy control mice (dotted black line); DSS+adCD-MSCs, DSS-treated mice which received adCD-MSCs (blue line); DSS+adCD-MSCs/hCBPL, DSS-treated mice which received adCD-MSCs resuspended in hCBPL (green line); DSS+hCBPL, DSS-treated mice which received hCBPL alone (pink line); DSS+PBS, DSS-treated mice which received PBS (red line). Data expressed as mean ± SEM. n = 4–12 mice per group. CTR vs. DSS+PBS, ****p <0.0001; DSS+adCD-MSCs/hCBPL vs. DSS+PBS, **p <0.01; hCBPL vs. DSS+PBS, p value not significant. b DAI calculated by the combined score of weight loss, stool consistency, and bleeding, as detailed in Additional file 1. DAI is evaluated daily from day +7 (first administration of adCD-MSCs or adCD-MSCs/hCBPL or PBS or hCBPL) to day +18. Representative time points are shown. Data expressed as mean ± SEM. n = 4–12 mice per group. DSS+adCD-MSCs and DSS+adCD-MSCs/ hCBPL vs. DSS+PBS, *p <0.05. adCD-MSC mesenchymal stromal cell isolated from adipose tissue of Crohn’s disease patients, DSS dextran sulfate sodium